Xbrane Biopharma AB financials
Xbrane Biopharma AB
Country: SE Reporting currency: SEK Latest annual report: 2024-12-31
LEI:
5493008DKD05APTKQO39 Financial statements
(SEK, as reported — unscaled; 99 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 198.7M | SEK 238.7M |
| Cost of sales | SEK 18.2M | SEK 203.3M |
| Gross profit | SEK 180.5M | SEK 35.4M |
| Other income | SEK 15.8M | SEK 13.7M |
| Administrative expenses | SEK 40.1M | SEK 40.0M |
| Operating profit (EBIT) | -SEK 217.9M | -SEK 322.2M |
| Net finance income / (cost) | -SEK 35.5M | SEK 137.0K |
| Finance costs | SEK 36.0M | SEK 2.3M |
| Profit before tax | -SEK 253.4M | -SEK 322.0M |
| Income tax expense | SEK 11.6M | SEK 0 |
| Profit for the year | -SEK 266.2M | -SEK 388.2M |
| — attributable to owners | -SEK 266.2M | -SEK 388.2M |
| — attributable to NCI | SEK 0 | SEK 0 |
| Total comprehensive income | -SEK 266.1M | -SEK 388.4M |
| Per share | ||
| Basic EPS | SEK -0.22 | SEK -0.66 |
| Diluted EPS | SEK -0.22 | SEK -0.66 |
| Free cash flow / share | SEK -0.11 | SEK -0.70 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 133.7M | -SEK 406.7M |
| Income taxes paid | SEK 11.6M | SEK 0 |
| Net cash from investing activities | -SEK 52.2M | -SEK 16.8M |
| Purchase of PP&E (capex) | SEK 501.0K | SEK 6.8M |
| Purchase of intangibles | SEK 51.7M | SEK 10.0M |
| Net cash from financing activities | SEK 243.6M | SEK 298.7M |
| Proceeds from borrowings | SEK 70.0M | SEK 225.0M |
| Lease liability payments | SEK 13.6M | SEK 13.9M |
| Net change in cash | SEK 57.6M | -SEK 124.8M |
| Balance sheet | ||
| Total assets | SEK 842.4M | SEK 653.5M |
| Non-current assets | SEK 236.5M | SEK 191.8M |
| Property, plant & equipment | SEK 23.9M | SEK 32.5M |
| Right-of-use assets | SEK 41.0M | SEK 55.7M |
| Intangible assets & goodwill | SEK 0 | SEK 0 |
| Current assets | SEK 605.9M | SEK 461.7M |
| Trade & other receivables | SEK 16.9M | SEK 0 |
| Cash & equivalents | SEK 124.3M | SEK 65.4M |
| Total equity | SEK 208.5M | SEK 171.3M |
| — attributable to owners | SEK 208.5M | SEK 171.3M |
| Non-controlling interests | SEK 0 | SEK 0 |
| Non-current liabilities | SEK 96.0M | SEK 155.6M |
| Lease liabilities (non-current) | SEK 29.6M | SEK 42.7M |
| Current liabilities | SEK 537.9M | SEK 326.6M |
| Lease liabilities (current) | SEK 13.3M | SEK 13.4M |
| Derived metrics | ||
| Free cash flow | -SEK 134.2M | -SEK 413.5M |
| Operating margin | -109.7% | -134.9% |
| Net margin | -134.0% | -162.6% |
| Return on equity | -127.7% | -226.6% |
| Cash conversion ratio | 0.50× | 1.05× |
| Capex coverage | -266.92× | -59.88× |
| Other reported items | ||
| Additional Paidin Capital | SEK 1.40B | SEK 1.43B |
| Adjusted Weighted Average Shares | 1229.9M | 592.1M |
| Adjustments For Decrease Increase In Inventories | -SEK 166.0M | -SEK 56.6M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 4.6M | -SEK 85.1M |
| Adjustments For Increase Decrease In Trade and Other Payables | SEK 212.8M | SEK 22.6M |
| Basic Earnings Loss Per Share From Continuing Operations | SEK -0.22 | SEK -0.54 |
| Cash | SEK 124.3M | SEK 65.4M |
| Cash and Cash Equivalents Classified As Part of Disposal Group Held For Sale | SEK 439.0K | SEK 645.0K |
| Cash Flows From Used In Financing Activities Discontinued Operations | SEK 0 | SEK 0 |
| Cash Flows From Used In Investing Activities Discontinued Operations | SEK 0 | SEK 0 |
| Cash Flows From Used In Operating Activities Discontinued Operations | -SEK 439.0K | -SEK 645.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 176.0M | -SEK 287.5M |
| Comprehensive Income Attributable To Noncontrolling Interests | SEK 0 | SEK 0 |
| Comprehensive Income Attributable To Owners of Parent | -SEK 266.1M | -SEK 388.4M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | SEK 188.4M | SEK 216.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | SEK 82.5M | SEK 62.5M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 198.9M | SEK 251.9M |
| Diluted Earnings Loss Per Share From Continuing Operations | SEK -0.22 | SEK -0.54 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 839.0K | -SEK 4.5M |
| Equity and Liabilities | SEK 842.4M | SEK 653.5M |
| Finance Income | SEK 501.0K | SEK 2.4M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 2.8M | SEK 3.0M |
| Increase Decrease Through Transactions With Owners | SEK 303.3M | SEK 134.8M |
| Intangible Assets Other Than Goodwill | SEK 167.7M | SEK 99.7M |
| Issue of Equity | SEK 344.9M | SEK 132.8M |
| Issued Capital | SEK 343.5M | SEK 6.7M |
| Liabilities | SEK 633.9M | SEK 482.2M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | SEK 407.0K | SEK 606.0K |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | SEK 2.0M | SEK 3.3M |
| Noncurrent Portion of Noncurrent Bonds Issued | SEK 66.4M | SEK 112.9M |
| Other Adjustments For Noncash Items | SEK 90.2M | SEK 100.7M |
| Other Comprehensive Income | SEK 111.0K | -SEK 201.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 111.0K | -SEK 201.0K |
| Other Current Nonfinancial Liabilities | SEK 10.7M | SEK 2.8M |
| Other Current Receivables | SEK 17.0M | SEK 34.2M |
| Other Expense By Function | SEK 61.2M | SEK 25.4M |
| Other Noncurrent Nonfinancial Liabilities | SEK 0 | SEK 8.0K |
| Other Noncurrent Receivables | SEK 3.9M | SEK 3.9M |
| Payments For Debt Issue Costs | SEK 0 | SEK 10.6M |
| Payments For Share Issue Costs | SEK 37.5M | SEK 962.0K |
| Proceeds From Issuing Other Equity Instruments | SEK 0 | SEK 18.0K |
| Proceeds From Issuing Shares | SEK 337.2M | SEK 120.0M |
| Profit Loss From Continuing Operations | -SEK 265.0M | -SEK 322.0M |
| Profit Loss From Discontinued Operations | -SEK 1.2M | -SEK 66.1M |
| Repayments of Bonds Notes and Debentures | SEK 112.5M | SEK 20.8M |
| Research and Development Expense | SEK 312.9M | SEK 305.8M |
| Reserve of Exchange Differences On Translation | SEK 10.2M | SEK 10.1M |
| Retained Earnings | -SEK 1.54B | -SEK 1.27B |
| Share Issue Related Cost | SEK 45.2M | SEK 962.0K |
| Trade and Other Current Payables To Trade Suppliers | SEK 242.6M | SEK 31.0M |
| Weighted Average Shares | 1230.0M | 592.1M |
| Work In Progress | SEK 246.9M | SEK 106.9M |
Methodology
Every line item above is a fact tagged in Xbrane Biopharma AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.